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Abstract 
Rationale: Radiotherapy combined with immunotherapy has revealed promising outcomes in both 
preclinical studies and ongoing clinical trials. Targeted radionuclide therapy (TRT) is a branch of 
radiotherapy concerned with the use of radioisotopes, radiolabeled molecules or nanoparticles that 
deliver particulate radiation to cancer cells. TRT is a promising approach in cases of metastatic 
disease where conventional treatments are no longer effective. The increasing use of TRT raises the 
question of how to best integrate TRT with immunotherapy. In this study, we proposed a novel 
therapeutic regimen that combined programmed death ligand 1 (PD-L1)-based immunotherapy with 
peptide-based TRT (177Lu as the radionuclide) in the murine colon cancer model.  
Methods: To explore the most appropriate timing of immunotherapy after radionuclide therapy, the 
anti-PD-L1 antibody (αPD-L1 mAb) was delivered in a concurrent or sequential manner when 177Lu 
TRT was given.  
Results: The results demonstrated that TRT led to an acute increase in PD-L1 expression on T cells, 
and TRT in combination with αPD-L1 mAb stimulated the infiltration of CD8+ T cells, which 
improved local tumor control, overall survival and protection against tumor rechallenge. Moreover, 
our data revealed that the time window for this combination therapy may be critical to outcome.  
Conclusions: This therapeutic combination may be a promising approach to treating metastatic 
tumors in which TRT can be used. Clinical translation of the result would suggest that concurrent 
rather than sequential blockade of the PD-1/PD-L1 axis combined with TRT improves overall 
survival and long-term tumor control. 
Key words: Targeted radionuclide therapy; immunotherapy; programed death ligand 1 (PD-L1); 177Lu-EB-RGD; 
combination treatment 
Introduction 
With the recent success of cancer 
immunotherapy, especially immune checkpoint 
blockade (ICB) therapy, there has been renewed 
interest in this treatment modality [1]. Several kinds of 
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ICB monoclonal antibodies (mAbs) have been applied 
in preclinical models of cancer and in patients, 
targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
[2], programmed death 1 (PD-1), PD-1 ligand 1 
(PD-L1) [3], transforming growth factor (TGF)-β [4], 
blocking immune checkpoints, and facilitating 
anti-tumor activity. Research has shown that PD-L1, 
which can inhibit CD8+ T-cell effector function by 
interacting with PD-1, is expressed on many types of 
tumor cells, tumor-associated macrophages (TAMs), 
and other cells in the tumor immune 
microenvironment [5]. Therefore, ICB using 
anti-PD1/PD-L1 mAbs has emerged as a promising 
treatment strategy in various types of malignancies. 
Indeed, the PD-1/PD-L1 mAbs pembrolizumab, 
nivolumab, and atezolizumab have been approved by 
the United States Food and Drug Administration 
(FDA) to treat patients with advanced non-small-cell 
lung carcinoma (NSCLC), head and neck squamous 
cell carcinoma (HNSCC), and melanoma [6-8].  
However, only 15-40% of patients respond to 
anti-PD1/PD-L1 mAbs; therefore, the population of 
patients benefiting from ICB therapy is still rather 
narrow [1]. As such, researchers must elucidate how 
to combine ICB therapy with other treatments. 
Recently, numerous studies have confirmed that 
systemic anti-tumor immunity is augmented 
following radiotherapy combined with ICB therapy 
targeting PD-1/PD-L1 in preclinical models of 
melanoma, breast cancer, lung cancer and colon 
cancer. [4, 9, 10]. These studies suggest that 
radiotherapy can induce a local inflammatory 
response and simultaneously upregulate PD-L1 
expression in the tumor microenvironment, which 
gives an opportunity to use anti-PD-L1 therapy 
following radiotherapy for enhancing the therapeutic 
benefits of immunotherapy in cancer [11]. Moreover, a 
range of preclinical models have suggested that 
irradiated tumor cells can act as an “in situ vaccine”, 
releasing tumor immunogenic antigen, enhancing 
immunogenicity, and inducing a systemic anti-tumor 
immune response outside of the irradiated tumor 
field [12, 13]. This has been termed the “abscopal 
effect” and may be further strengthened in the 
presence of immunotherapy [12, 14]. More recently, 
phase III PACIFIC clinical trial has demonstrated that 
the αPD-L1 mAb (Durvalumab) combined with 
concurrent chemoradiotherapy could extend overall 
survival than standard chemoradiotherapy [15]. 
Taken together, the combination of radiotherapy with 
PD1/PD-L1 mAbs shows improved anti-tumor 
efficacy, providing a rationale for this combined 
therapeutic strategy.  
Targeted radionuclide therapy (TRT) is a branch 
of radiotherapy that uses radionuclides, radiolabeled 
molecules, or nanoparticles that either naturally 
accumulate in or are designed to target tumors. 
Unlike external-beam radiotherapy, which mostly 
acts locally on primary tumors, TRT can also be used 
to treat metastatic tumors because it can be 
administered systemically [16]. The major difference 
between the two forms of radiotherapy is dose rate. 
External-beam radiotherapy is delivered at high dose 
rates, typically about 6 Gy/min in short, repeated 
daily fractions of about 2 Gy. In TRT, however, the 
absorbed dose is delivered continuously but slowly, 
with a dose rate of 0.01–1.00 Gy/h that tapers over 
time as the radionuclide decays [16]. Another 
difference lies in the absorbed dose. Regarding TRT, a 
high inter-patient variability of the mean absorbed 
doses to lesions was found that could be explained by 
variable receptor densities between individuals and 
different types of targeting vectors. In general, it 
should be noted that on average the absorbed dose of 
TRT was less than those achieved with external beam 
radiotherapy. For example, the mean absorbed doses 
in tumor lesions for 177Lu-PSMA-617, 
177Lu-DOTA-TATE and 177Lu-DOTA-TOC are 13.1, 9.7 
and 7.5 Gy/GBq, respectively [17, 18]. Differing dose 
rates and absorbed doses have been shown to cause 
differences in gene expression, mode of cell death, 
and type of DNA damage that is induced [19, 20]. 
However, the radiobiological effects of the two forms 
of radiotherapy must be better understood. 
Peptide-radiometal conjugates that bind to cell 
surface somatostatin receptors have been used 
clinically for many years in an approach known as 
peptide receptor radionuclide therapy (PRRT). On 
January 26, 2018, the FDA approved 177Lu-labeled 
dodecanetetraacetic acid tyrosine-3-octreotate 
(DOTA) to treat somatostatin receptor-positive 
gastroenteropancreatic neuroendocrine tumors [21]. 
More recently, 177Lu-labeled prostate specific 
membrane antigen ligand has been tested in 
metastatic castration-resistant prostate cancer, with 
promising preliminary results [22, 23].  
Since there is evidence from preclinical and 
clinical studies to suggest that external-beam 
radiotherapy boosts the therapeutic benefits of 
immunotherapy, researchers must now elucidate how 
to best combine TRT with immunotherapy. To this 
end, they must design therapeutic protocols that 
combine the strengths of TRT with those of 
immunotherapy, taking into consideration optimal 
timing and sequencing. In the present paper, we 
proposed a novel therapeutic regimen combining 
PD-L1-based immunotherapy with PD-L1 antibody 
treatment with peptide-based TRT. The peptide 
containing Arg-Gly-Asp (RGD) sequence specifically 
targets the cell surface receptor integrin αvß3, which is 
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overexpressed in various malignancies [24]. As such, 
RGD was identified as a promising radionuclide 
vector and was modified for TRT application in the 
present study. To further enhance the efficacy of TRT, 
the RGD peptide was chemically conjugated with an 
albumin-binding moiety—truncated Evans Blue 
(denoted as EB-RGD). In our previous study, EB-RGD 
showed significantly higher tumor uptake and tumor 
residence time than RGD monomer [25]. In the 
present study, EB-RGD was labeled with the 
β-emitting radionuclide 177Lu for TRT purposes. 
Furthermore, to evaluate the most appropriate timing 
of immunotherapy after radiotherapy, the anti-PD-L1 
mAb was delivered in a concurrent or sequential 
manner when 177Lu TRT was given. Through this 
investigation, we aimed to explore whether this 
combined therapeutic regimen would synergistically 
enhance anti-tumor efficacy and to propose a 
rationale for the combination of TRT and 
immunotherapy.  
Materials and methods 
General 
All chemicals were purchased from 
Sigma-Aldrich Chemical Co. or Thermo Fisher 
Scientific. EB-NH2 was synthesized as described 
previously [26, 27]. Cyclic-(Arg-Gly-Asp-D-Phe-Lys) 
(RGD) peptide was purchased from C.S. Bio. 
InvivoPlus anti-mouse PD-L1 mAb was purchased 
from BioXCell (Cat. No. BP0101). The murine colon 
adenocarcinoma cell line, MC38, was purchased from 
the China National Infrastructure of Cell Line 
Resource. Labeling efficiency and radiochemical 
purity were tested using a Mini-Scan radio-TLC 
Scanner (BioScan, USA) and Dionex Ulti-Mate 3000 
high performance liquid chromatography (HPLC; 
Thermo Scientific, USA), with a flow-counter 
radioactivity detector (BioScan, USA). Radioactivity 
was measured using a γ-counter (WIZARD 2480; 
Perkin-Elmer, USA) and CRC-25R Dose Calibrators 
(CAPIN-TEC Inc., USA). SPECT imaging was 
performed using a nanoScan SPECT/CT scanner 
(Mediso, Hungary). 
Chemistry and radiochemistry 
EB-RGD was synthesized as in our previous 
study [25]. Briefly, EB-RGD was prepared by linking 
truncated Evans Blue molecules to a lysine spacer, 
attaching a chelator to the α-amine, attaching 
maleimide to the ε-amine, and attaching the thiolated 
RGD peptide to the maleimide. DOTA was used as 
the chelator to allow complexation with the 
radionuclide 177Lu.  
High-purity lutetium chloride was obtained 
from itG (Germany) as a sterile solution of 177LuCl3 in 
0.05 M HCl, with a radionuclide purity of > 99%. For 
radiolabeling, either 1.85 GBq (50 mCi, for EB-RGD) 
or 0.55 GBq (15mCi, for DOTA-RGD) of 177LuCl3 was 
diluted using 0.3 mL of 0.5 M NH4OAc (pH = 5.6); 
EB-RGD (50 μg dissolved in 10 μL absolute ethyl 
alcohol) or RGD (50 μg dissolved in 100 μL metal-free 
water) was then added. The mixture was heated for 30 
min at 90 °C, purified using a C18 cartridge, and 
passed through a 0.22-μm aseptic filtration 
membrane. Radiochemical purity control was 
performed using analytical thin-layer 
chromatography (Bioscan, USA). CH3OH:NH4OAc 
(v/v 1:1) was used as the developing solution.  
Preparation of tumor-bearing mice 
Seven- to 8-week-old female C57BL/6 mice from 
Beijing Vital River Laboratory Animal Technology 
Co., Ltd. were used in the present study. All animal 
studies were approved by the Animal Care and Use 
Committee of the First Affiliated Hospital of Xiamen 
University. The MC38 murine colon adenocarcinoma 
was selected as the tumor model in this study. This 
tumor model is generally PD-L1 positive expression 
and is used as an immunoresponsive murine model in 
many immunological researches [28]. Besides, 
previous study has confirmed that this tumor model 
has a positive expression of integrin αvß3 [29]. To 
induce MC38 tumors, 106 cells in PBS (pH=7.4) were 
injected subcutaneously into the right rear flank of 
each mouse. The mice then received either saline, 
anti-PD-L1 mAb, 177Lu-EB-RGD, or combined therapy 
when the tumor volume reached about 100 mm3 (7 
days after inoculation) and underwent small animal 
SPECT imaging studies when the tumor volume 
reached 200 mm3 (10–12 days after inoculation).  
SPECT imaging and biodistribution study 
SPECT was performed using a four-head 
multiplexing multipin hole camera (Mediso, 
Hungary). Healthy MC38 tumor-bearing female 
C57BL/6 mice were intravenously injected with 17–18 
MBq of either 177Lu-EB-RGD (n = 4) or 177Lu-RGD (n = 
4). Whole body SPECT images were acquired at 4, 24, 
48, 72, and 96 hours post injection (p.i.). SPECT 
images were obtained with a time-per-view of 30–60 
seconds, resulting in a scan time of 25–60 min 
(window width: 20%, matrix: 256 × 256, medium 
zoom). After acquisition, SPECT data were 
reconstructed iteratively with a software 
(Tera-TomoTM) using 177Lu γ-energies of 56.1, 112.9, 
and 208.4 keV. The SPECT images were analyzed 
using InVivoScope software (Bioscan Inc.). To 
quantify the radioactive signals in mouse tumors and 
other tissues, regions of interest (ROIs) were drawn 
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and counted on the SPECT images of tumor, liver, 
heart, and muscle. The results were expressed as 
tumor-to-muscle (T/M), liver-to-muscle (L/M), and 
blood-to-muscle (B/M) ratios.  
For the biodistribution study, C57BL/6 mice 
bearing MC38 tumors and injected with 
177Lu-EB-RGD (0.5 MBq) were sacrificed at 4, 24, 48, 
and 72 h p.i. Blood, muscle, bone, liver, kidneys, 
spleen, intestine, heart, lung, muscle, brain, stomach, 
and tumor were collected and wet weighed. The 
biodistribution of 177Lu-RGD was also measured for 
comparison. Mice bearing MC38 tumors were 
sacrificed at 4 h p.i. and their main organs were 
collected and weighed. Radioactivity was assayed 
using a γ-counter, and the results were expressed as 
percentage of injected dose per gram (%ID/g). 
In vivo therapy regimen 
One week after inoculation with MC38 tumor 
cells, C57BL/6 mice were divided into five treatment 
groups of 9 to 10 mice per group: Group A received 
saline, Group B, 18.5 MBq of 177Lu-EB-RGD by 
intravenous (i.v.) injection, Group C, anti-PD-L1 mAb 
on days 0, 3, and 6 at a dose of 10 mg/kg by 
intraperitoneal (i.p.) injection, Group D received 
concurrent combined therapy, with 18.5 MBq of i.v. 
177Lu-EB-RGD given on day 0 and 10 mg/kg i.p. of 
anti-PD-L1 mAb given on days 1, 4 and 7, and Group 
E received sequential combined therapy, with 18.5 
MBq of i.v. 177Lu-EB-RGD given on day 0 and 10 
mg/kg of i.p. anti-PD-L1 mAb given on days 11, 14, 
and 17. The overall therapy regimen is shown in 
Figure 1.  
To evaluate the anti-tumor efficacy of the 
treatment, tumor volume and body weight were 
monitored every 2 days. Individual tumor size was 
calculated using the following formula: length × 
width × width)/2. Groups A, B, C, and D underwent 
18F-FDG positron emission tomography (PET) 
imaging 3 days after the start of treatment. The PET 
imaging protocol and analysis were performed as 
previously described [30], except that the animals 
were fasted for 4 h before 18F-FDG PET.  
The endpoint criteria for Kaplan–Meier analysis 
were as follows: weight loss of > 15%, tumor volume 
of > 1,500 mm3, active tumor ulceration, and abnormal 
behavior indicating pain or unease.  
Flow cytometry 
The mouse tumor tissue was obtained and the 
necrotic tissues and fat were removed. The tumor 
tissue was cut into small pieces (about 2 mm) and 
placed in Dulbecco’s modified Eagle’s medium with 1 
mg/mL collagenase IV (Sigma-Aldrich, Cat. No. 
C5138) and 0.1 mg/mL DNase I (Sigma-Aldrich Cat. 
No. D4527) for 30–40 minutes at 37 ºC. The cell 
suspension was then filtered through a cell strainer, 
washed with cell staining buffer (BD PharmingenTM; 
Cat. No. 554656), and centrifuged for 7 min at 300 × g. 
The supernatant was then discarded.  
Viable cells were counted and resuspended in 
cell staining buffer at a concentration of 5–10 × 106 
cells/mL. Next, 100 µL/tube of cell suspension (5–10 
x 105 cells/tube) was distributed into 2-mL plastic 
tubes. Fc receptors were then blocked by 
pre-incubation in 1 µg of purified anti-mouse 
CD16/CD32 mAb (BD PharmingenTM, Cat. No. 
553141) per 106 cells in 100 µL at 4 ºC for 5 min. Then, 
 
 
Figure 1. Design of therapy protocol. Group A received saline. Group B received 18.5 MBq of 177Lu-EB-RGD targeted radionuclide therapy (TRT) by intravenous injection. 
Group C received anti-PD-L1 mAbs (αPD-L1 mAb) immunotherapy at a dose of 10mg/kg by intraperitoneal injection (d 0, 3 and 6). Group D received concurrent combined 
therapy with 177Lu-EB-RGD (d 0) and αPD-L1 mAb (d 1, 4 and 7), and group E received sequential combined therapy with 177Lu-EB-RGD (d 0) and αPD-L1 mAb (d 11, 14 and 
17). 
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100 μL of cells per tube were incubated with 
fluorescent mAbs specific to mouse CD45, CD11b, 
CD274, CD3e, or CD8α (BD PharmingenTM; Cat. Nos. 
553018, 557396, 564715, 553061, and 553032, 
respectively) for 30 min at 2 –8 °C. The tubes were 
then washed once in 2 mL of stain buffer and 
centrifuged at 350 × g for 5 min. According to the 
intracellular staining protocol for FoxP3 staining (BD 
PharmingenTM; Cat. No. 563101), the cells were 
analyzed and data acquired using the ACEA 
NovoCyte Flow Cytometer. 
Multiplexed immunofluorescence 
Multiplexed immunofluorescence (IF) was 
performed by sequentially staining 4-µm-thick 
formalin-fixed, paraffin-embedded whole tissue 
sections with standard, primary mAbs paired with a 
unique fluorochrome, followed by staining with 
DAPI. For example, deparaffinized slides were 
incubated with anti-CD8 mAb (#CST98941; Cell 
Signaling Technology) for 30 min and then treated 
with anti-rabbit horseradish peroxidase 
(HRP)-conjugated secondary mAb (PV-6001; 
Zhongshan Bio) for 10 min. IF labeling was then 
developed for 10 min using Alexa Fluor™ 488-labeled 
tyramide (Thermo Fisher; B40953), as per the 
manufacturer’s instructions. The slides were then 
washed in Tris buffer for 5 min, transferred into 
preheated citrate solution (90 °C), and heat-treated 
using a microwave set at 20% maximum power for 15 
min. The slides were cooled in the same solution to 
room temperature (RT). Between all steps, the slides 
were washed in Tris buffer. The same process was 
repeated for the following mAbs and fluorescent 
dyes, in order: Anti-CD11b mAb (Abcam, 
ab133357)/Alexa Fluor™ 647-labeled tyramide, CD45 
rabbit mAb (Cell Signaling Technology)/Alexa 
Fluor™ 488-labeled tyramide, CD274 mAb (Absin; 
abs136046)/Alexa Fluor™ 594-labeled tyramide, 
CD8α mAb (Cell Signaling Technology; 98941)/Alexa 
Fluor™ 546-labeled tyramide. Each slide was then 
treated with two drops of DAPI (D1306; Thermo 
Fisher), washed in distilled water, and manually 
cover-slipped. The slides were then air-dried and 
mounted with Prolong Diamond Anti-fade mounting 
medium (P36965; Thermo Fisher). Pictures were taken 
with the Aperio Versa 8 tissue imaging system (Leica). 
Images was analyzed using Indica Halo software. 
Histopathological staining after therapy 
MC38 tumor samples from groups A-D were 
collected and sectioned at day 7 after therapy, and 
samples from group E were collected at day 14 after 
therapy. To visualize the endothelial cells, CD31 
immunohistochemistry was performed. In brief, 
tumor sections were fixed using cold acetone and 
rinsed in PBS; endogenous peroxidase activity was 
blocked with a 3% H2O2 aqueous solution for 10 mins 
and unspecific binding of proteins was blocked by 
using 1% bovine serum albumin solution for 1 h at RT. 
The slides were incubated with a 1:100 dilution of 
anti-mouse CD31 (Abcam, ab9498) mAb at RT 
overnight and then incubated with 
peroxidase-conjugated rabbit-anti-mouse secondary 
mAb. Next, 3,3’-diaminobenzidine (DAB) was used to 
visualize peroxidase activity in the sections. For Ki-67 
staining, tumor sections were fixed with cold acetone 
for 20 min and then air-dried for 30 min at RT. 
Blocking was achieved using 1% bovine serum 
albumin for 30 min, and the slides were stained with 
Ki-67-specific mAb (Abcam; ab15580) then incubated 
with peroxidase-conjugated rabbit-anti-mouse 
secondary mAb. DAB was then used to visualize 
peroxidase activity in the sections. 
Immunofluorescent terminal deoxynucleotidyl 
transferase–mediated dUTP-biotin nick-end labeling 
(TUNEL) analysis was carried out using a 
commercially available kit (Roche Applied Science). 
In accordance with the manufacturer’s specifications, 
samples were fixed using 10% formalin and 
permeabilized in 0.1% Triton for 2 min on ice. Next, 50 
mL of TUNEL reaction mixture were added to the 
samples. The slides were incubated in a humidified 
atmosphere for 60 min at 37 ºC in the dark. After 
rinsing in PBS and mounting in a DAPI-containing 
medium, the samples were observed under an 
epifluorescence microscope in the green fluorescent 
protein channel. Hematoxylin and eosin staining of 
mouse tissues was conducted by Univ-Bio Inc. 
Statistics 
Quantitative data were expressed as mean ± SD. 
Means were compared using one-way analysis of 
variance and Student’s t test. P value of < 0.05 was 
considered statistically significant. 
Results 
Preparation of radiolabeled compounds 
In the present study, we prepared two 
radioligands: 177Lu-EB-RGD, which has high affinity 
for integrin and contains an albumin binding moiety, 
and 177Lu-RGD, which has high affinity for the 
integrin receptor but lacks the albumin-binding 
moiety. The 177Lu-EB-RGD and 177Lu-RGD were 
radiolabeled at an average specific activity of 55.85 ± 
14.0 and 18.6 ± 4.7 GBq/μmol, respectively, with 
greater than 95% radiochemical purity after 
purification.  
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SPECT imaging and biodistribution of 
177Lu-EB-RGD in MC38 tumor-bearing mice 
To investigate the in vivo behavior of 
177Lu-EB-RGD, we performed small-animal SPECT 
imaging studies. Representative whole-body SPECT 
images of C57BL/6 mice bearing MC38 tumors are 
shown in Figure 2. In the case of 177Lu-EB-RGD, high 
tumor-to-background ratio (T/M: 9.03 ± 0.44) was 
observed 4 h p.i., with the tumor uptake peaking at 24 
h p.i. (T/M: 14.87 ± 0.88) and reduced slightly over 
time. Meanwhile, 177Lu-EB-RGD uptake in the blood 
was relatively high at 1 h p.i. (B/M: 5.22 ± 0.23) but 
decreased gradually from 24 to 96 h p.i. The 177Lu 
signal was also observed in the liver and kidneys, 
which also decreased from 24 to 96 h p.i. The 
clearance of 177Lu-EB-RGD from non-target tissues 
allowed the tumor isografts to be visualized (Figure 
2A). SPECT imaging with 177Lu-RGD was also 
performed in MC38 tumor-bearing mice (Figure 2B). 
Compared with 177Lu-EB-RGD, 177Lu-RGD was 
rapidly cleared from the blood through the urinary 
tract and showed significantly lower accumulation in 
tumors (T/M: 2.90 ± 0.30) at 4 h p.i. The encouraging 
high tumor uptake of 177Lu-EB-RGD, coupled with 
prolonged tumor retention time resulted in high 
exposure to the radioactive isotope, as evidenced 
from area under the curve calculated from non-decay 
corrected data (Figure 2C).  
The biodistribution of 177Lu-EB-RGD in MC38 
tumor-bearing mice was obtained through ex vivo 
counting in tissues collected from mice that were 
sacrificed at different p.i. time points (Figure 3A). The 
results obtained from these studies were generally 
consistent with previous observations from SPECT 
imaging. At 4 h p.i., 177Lu-EB-RGD was mainly 
accumulated in the blood (10.54 ± 2.21 %ID/g) and 
blood rich organs such as the liver (10.92 ± 5.77 
%ID/g) and spleen (13.44 ± 4.11 %ID/g). Moreover, 
177Lu-EB-RGD was cleared predominantly through 
the renal pathway, as evidenced by the high kidney 
uptake (18.13 ± 4.87 %ID/g). Tumor uptake at this 
time was 11.99 ± 1.60 %ID/g, and tumor-to-blood 
(T/B) ratio was 1.40 ± 0.39. By 24 h p.i., 177Lu-EB-RGD 
in the blood, liver, spleen, and kidneys had decreased 
to 3.23 ± 1.47, 10.29 ± 2.32, 13.11 ± 2.29, and 14.55 ± 
2.09 %ID/g, respectively, whereas the tumor uptake 
and T/B ratio had increased to 14.78 ± 4.74 %ID/g 
and 4.79 ± 0.97, respectively. At 48 h p.i., 
177Lu-EB-RGD tumor uptake had decreased slightly to 
14.26 ± 2.73 %ID/g, while the uptake in blood (1.96 ± 
0.58 %ID/g), liver (9.78 ± 1.21 %ID/g), spleen (12.19 ± 
5.06 %ID/g), and kidneys (13.80 ± 2.73 %ID/g) had 
continued to decrease. Further clearance of 
177Lu-EB-RGD from all organs was seen at 72 h p.i, 
with T/B ratio further increased to 6.35 ± 0.18. The 
biodistribution of 177Lu-RGD was also observed by 
way of comparison (Figure 3B).  
Consistent with the SPECT findings, 
177Lu-EB-RGD demonstrated significantly longer 
blood half-life than 177Lu-RGD, and the blood uptake 
of 177Lu-EB-RGD was nearly 18 times greater than that 
of 177Lu-RGD (10.54 ± 2.21 vs. 0.56 ± 0.06 %ID/g at 4 h 
p.i.). As a result, 177Lu-EB-RGD exhibited significantly 
higher tumor uptake than 177Lu-RGD (11.99 ± 1.60 vs. 
3.69 ± 0.37 %ID/g 4 h p.i.).  
Combination of TRT and anti-PD-L1 antibody 
synergistically enhances anti-tumor efficacy in 
MC38 tumors 
To investigate whether combined therapy would 
be more efficacious than 177Lu-EB-RGD or anti-PD-L1 
mAb alone, a study was performed with five groups 
(A–E), each including 9–10 MC38 tumor-bearing mice. 
The anti-tumor efficacy of each treatment was 
monitored over 2 months. The therapy protocols 
along with the relative tumor volumes and body 
weights of the mice from each group are shown in 
Figure 4A. 
 
 
Figure 2. (A) Projection SPECT images of MC38 tumor bearing mice at 4, 24, 48, 72 and 96 h after injection of 18.5 MBq 177Lu-EB-RGD (n = 4). (B) Projection SPECT images 
of MC38 tumor bearing mice at 1 and 4 h after injection of 18.5 MBq 177Lu-RGD (n = 4). (C) Area under the curves (AUC) of 177Lu-EB-RGD (blue) and 177Lu-RGD (purple) 
calculated from the radioactivity accumulation in the tumor over time. Arrows indicate tumor location.  
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Figure 3. (A) Biodistribution of 177Lu-EB-RGD in MC38 tumor bearing mice at 4, 24, 48 and 72 h post-injection (n = 4/group). (B) Biodistribution comparison of 177Lu-EB-RGD 
and 177Lu-RGD in MC38 tumor bearing mice at 4 h post-injection (n = 4/group).  
 
Figure 4. (A) Design of therapy protocol. (B) Body weight change. (C) Tumor volume. (D) Survival of mice (9-10/group) treated with saline (group A), 177Lu-EB-RGD (group B), 
αPD-L1 mAb (group C), concurrent combined therapy with 177Lu-EB-RGD and αPD-L1 mAb (group D) and sequential combined therapy with 177Lu-EB-RGD and αPD-L1 mAb 
(group E) at different days after treatment. (E) Projection PET images of MC38 tumor bearing mice injected with 18F-FDG 3 d after treatment with saline (group A), 177Lu-EB-RGD 
(group B), αPD-L1 mAb (group C) and combined therapy with 177Lu-EB-RGD and αPD-L1 mAb (group D). White arrows indicate the tumor location. (F) PET quantification of 
the images in Fig 4E. *P < 0.05, ** P < 0.01 
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No systemic radiotherapy-related toxicity, as 
indicated by the animals’ body weight, was observed 
(Figure 4B). Rapid tumor growth was observed in 
mice treated with saline (Group A), and all mice in 
this group had to be euthanized by day 24 due to 
excessive tumor volume (Fig 4C; green line). In mice 
treated with 177Lu-EB-RGD alone (Group B) and in 
those treated using anti-PD-L1 mAb alone (Group C), 
a significant delay in tumor growth was observed 
(Figure 4C; orange and blue lines). Starting from day 
6, a significant difference in tumor volume was 
observed between the anti-PD-L1 mAb-treated and 
saline-treated groups (P = 0.007), while a significant 
difference between the 177Lu-EB-RGD and 
saline-treated group was observed from day 8 (P = 
0.001). Mice in Groups B and C survived until day 39 
and day 33 of the study, respectively, representing 
significantly greater survival than control mice (P < 
0.0001 for both Groups B and C) (Figure 4.D). During 
treatment, a partial response (PR) was observed in 
two of nine mice treated with 177Lu-EB-RGD and in six 
of 10 mice treated with anti-PD-L1 mAb, but relapse 
was observed a few days later in both groups.  
Next, enhancement of anti-PD-L1 
immunotherapy by combination with 177Lu-EB-RGD 
was assessed. To evaluate the most appropriate 
timing of immunotherapy after radiotherapy, the 
anti-PD-L1 mAb was delivered in a concurrent or 
sequential manner with 177Lu TRT. The greatest 
therapeutic efficacy was observed in the concurrent 
combined therapy group (Group D), with further 
marked inhibition of tumor growth (Figure 4C; red 
line). Starting from day 8, significant differences in 
tumor volume were observed between Groups B and 
D (P = 0.013), while significant differences between 
Groups C and D were observed from day 10 after 
treatment (P = 0.034). These differences increased over 
time; most tumors had started to shrink by day 6 and 
had completely disappeared by day 26. During 
treatment, 2 of 10 mice showed PR, while 8 of 10 
showed complete response (CR), with all of these 
maintaining CR for the duration of the study (until 
day 50). Therefore, mice that received concurrent 
combined therapy of 177Lu-EB-RGD and anti-PD-L1 
mAb showed significantly better survival than those 
treated using 177Lu-EB-RGD alone (P < 0.0001) or 
anti-PD-L1 mAb alone (P < 0.0001) (Figure 4D). 
Moreover, 4 of the mice with complete tumor 
regression were rechallenged with 106 MC38 cells on 
day 80, to further investigate whether immunologic 
memory was generated following treatment with TRT 
and anti-PD-L1 mAb. The results indicated that all 4 
mice were able to completely reject rechallenged 
tumors. 
In the group that received sequential combined 
therapy of 177Lu-EB-RGD and anti-PD-L1 mAb 
(Group E), a slightly less profound therapeutic 
efficacy was observed than in the group that received 
concurrent combined therapy (Group D), with the 
tumor volumes in Group E being slightly larger than 
those in Group D from day 8 after treatment (P = 
0.007), but still significantly smaller than those in 
Groups B and C from day 16 until the end of the study 
(Figure 4C; purple line). CR was observed in 2 of 10 
mice, while PR was observed in 4 of 10. Additionally, 
in Group E, survival was greater than that in Group B 
(P = 0.0007) and Group C (P < 0.0001), but not greater 
than that in Group D, wherein the mice survived until 
the end of the study (Figure 4D). 
During treatment, we evaluated tumor 
metabolism using appropriate PET tracers. 
Specifically, 18F-FDG PET imaging, an indicator of 
cellular metabolism, was conducted 3 days after the 
initial treatment and showed significantly less 
18F-FDG uptake in Groups B (treated with 
177Lu-EB-RGD) and D (177Lu-EB-RGD radiotherapy 
concurrent with anti-PD-L1 immunotherapy) than 
that in the saline-treated group (Figure 4E). In 
addition, the difference between control and therapy 
group is smaller when the tumor-to-background ratio 
was used for quantification, but significant difference 
in Group B (8.32 ± 1.25 vs. 6.22 ± 0.92, P < 0.05) and 
Group D (8.32 ± 1.25 vs. 5.89 ± 0.92, P < 0.05) can still 
be observed. These results suggested reduced tumor 
metabolism in these mice. The mice treated using 
anti-PD-L1 mAb alone (Group C) also showed 
decreased FDG uptake compared to the control 
group, although this difference was not statistically 
significant (Figure 4F).  
Tumor biology after 177Lu targeted 
radionuclide therapy 
CD31 staining to evaluate tumor vasculature, 
Ki-67 staining to evaluate tumor proliferation, and 
TUNEL staining to determine DNA damage were 
conducted on excised tumors in all five groups (A–E). 
In Groups D and E, which had large necrotic areas, we 
evaluated live cells on the tumor rim. As shown in 
Figure 5, the tumor vasculature in Group D 
(concurrent therapy using 177Lu-EB-RGD and 
anti-PD-L1 mAbs) had the lowest extent of all groups. 
Moreover, a relatively high percentage of cells stained 
positively for Ki-67 in Groups A, B, and C, while 
significantly reduced cell proliferation was observed 
in Groups D and E. Compared with the other four 
groups, Group D showed considerably more cell 
apoptosis, as depicted by TUNEL staining. 
Hematoxylin and eosin staining showed that most of 
the tumor area in Group D was already necrotic 7 
days after the initial treatment, whereas tumors from 
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the other four groups only had necrotic areas in the 
middle of the tumor, suggesting that the necrosis was 
due to insufficient blood supply and hypoxia.  
TRT up-regulates PD-L1 expression while TRT 
in combination with anti-PD-L1 antibody 
increases the infiltration of CD8+ T cells 
To investigate alterations in the tumor 
microenvironment after TRT and immunotherapy 
and thus further elucidate the potential mechanisms 
of TRT combined with immunotherapy, PD-L1+ 
immune cells (CD45+/PD-L1, CD11b+/PD-L1), 
PD-L1+ neoplastic cells (CD45-/PD-L1), CD8+ T cells 
and tumor-infiltrating regulatory T cells 
(CD4+/Foxp3+) were assessed dynamically using both 
flow cytometry and multiplexed 
immunofluorescence. The flow cytometry analysis 
showed that, compared with the saline-treated control 
group (Group A), percentage of CD45+/PD-L1+ cells 
and CD11b+/PD-L1+ cells on day 4 were significantly 
increased in MC38 tumor-bearing mice treated using 
177Lu TRT (Group B), whereas no significant 
difference was observed in the level of CD45-/PD-L1 
and CD4+/ Foxp3+ cells between the control and 
therapeutic groups (Group B-D) (Figure 6A). 
However, on day 14 after the initial treatment, the 
levels of PD-L1-expressing CD45+ cells and CD11b+ 
cells in the group of 177Lu TRT (Group B) were 
significantly lower than those in the control group 
(Figure 6B). Moreover, MC38 tumors that had been 
subjected to concurrent therapy of TRT and 
anti-PD-L1 mAb (Group D) exhibited significantly 
more CD3+/CD8+ T cells than saline-injected controls, 
whereas this finding was not observed in mice treated 
using sequential therapy (Group E) (Figure 6B). 
Multiplexed immunofluorescence analysis 
revealed similar results. Representative images of 
tumor section slides with multiplexed 
immunofluorescence staining are shown in Figure 7A. 
The levels of CD45+/PD-L1+ cells and 
CD11b+/PD-L1+ cells were significantly higher on 
days 4 and 7 in mice treated using 177Lu TRT than in 
saline-injected controls, whereas no significant 
difference was observed on day 14 (Figure 7 B-C). 
Moreover, the level of CD8+ T cells was significantly 
higher in mice treated using either concurrent (day 4 
and 7) or sequential (day 14) combined therapy 
(Figure 7D). Taken together, these data indicate that 
TRT led to an acute increase in PD-L1 expression on T 
cells, and that TRT combined with anti-PD-L1 mAb 
synergistically enhances anti-tumor immunity by 
stimulating CD8+ T cell infiltration.  
 
 
Figure 5. Immunofluorescence staining of excised tumors for CD31 (vascularity), Ki-67 (proliferation), TUNEL (apoptosis), and hematoxylin and eosin (H&E) after treatment 
with saline (group A), 177Lu-EB-RGD (group B), αPD-L1 mAb (group C), concurrent combined therapy with 177Lu-EB-RGD and αPD-L1 mAb (group D) and sequential combined 
therapy with 177Lu-EB-RGD and αPD-L1 mAb (group E). Tumor samples from groups A-D were collected at d 7 after treatment, and samples from group E were collected at d 
14 after treatment (αPD-L1 mAb starting on d 11 of TRT).  
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Figure 6. (A-B) Percentage of PD-L1+ immune cells (CD45+/PD-L1+, CD11b+/PD-L1+), PD-L1+ neoplastic cells (CD45-/PD-L1), CD8+ T cells and tumor-infiltrating regulatory T 
cells (CD4+/foxp3+) in MC38 tumors, which were measured by flow cytometry 4 d (A) and 14 d (B) after treatment with saline (green), 177Lu TRT (orange), αPD-L1 mAb (blue), 
concurrent combined therapy with 177Lu TRT and αPD-L1 mAb (red) or sequential combined therapy with 177Lu TRT and αPD-L1 mAb (purple) (n = 4/group). TRT = targeted 
radionuclide therapy. *P < 0.05, **P < 0.01, ***P<0.001. 
 
 
Figure 7. (A) Multiplexed immunofluorescence staining for PD-L1 (pink), CD11b+ (red), CD45+ (green), CD8+ (yellow) and DAPI (blue) in MC38 tumors, which were 
measured 4 d (left), 7 d (middle) and 14 d (right) after treatment with saline (control), 177Lu-EB-RGD targeted radionuclide therapy (TRT), concurrent combined therapy with 
177Lu TRT and αPD-L1 mAb (day 4 and 7) or sequential combined therapy with 177Lu TRT and αPD-L1 mAb (day 14). Scale bar is 200μm (magnification, × 20). (B-D) Quantified 
results for multiplexed immunofluorescence staining presented in Figure 7A at different time points. *P < 0.05, **P < 0.01, ***P<0.001. 
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Discussion  
Blockade of the PD-1/PD-L1 axis has shown 
encouraging efficacy across multiple malignancies, 
with mAbs targeted against either PD-1 or PD-L1. 
Nonetheless, combination approaches may be 
required to improve response rates and generate 
durable anti-tumor immunity. There is substantial 
evidence to suggest that the tumor-specific immune 
response is subsequently triggered and enhanced 
during combinatorial treatment of radiotherapy and 
immunotherapy [31, 32]. TRT is a branch of 
radiotherapy and flexibility is built into this system 
because TRT can be used to treat both localized and 
metastatic tumors through locoregional or systemic 
administration. Therefore, researchers must now 
elucidate how to best combine TRT with 
immunotherapy.  
In the year of 2018, Jaeyeon et al. firstly reported 
the combination of TRT and immune checkpoint 
inhibitors (ICIs) in B16-F10 melanoma model [33]. The 
results demonstrated that TRT in combination with 
ICIs showed significantly enhanced overall survival 
as compared with TRT or ICIs alone. However, the 
optimum timing between the 2 therapies and the 
underlie mechanism of combinatory therapy require 
further investigation. To address the limitation of this 
previous study, we explored the effect of PD-L1 
blockade when combined with TRT in either 
concurrent or sequential administration in the present 
study. Consistent with the previous research, our data 
demonstrate that anti-PD-L1 mAb combined with 
177Lu-EB-RGD, an integrin αvß3-targeted TRT, 
improve anti-tumor efficacy and prolong overall 
survival compared with either treatment alone. The 
underlying mechanism is that TRT leads to acute 
inflammation and cell death which results in the 
migration of immune cells to the tumor site, thereby 
TRT can modulate the tumor microenvironment to 
activate immune response and thereafter enhance 
anti-tumor efficacy.  
Previous studies have demonstrated that the 
PD-1/PD-L1 axis plays an essential role in host 
immune surveillance and in the regulation of the 
tumor microenvironment [32]. Therefore, inhibition of 
this pathway may induce the immune response and 
generate long-lasting anti-tumor responses to 
radiotherapy. Indeed, in our present study, PD-L1 
expression was up-regulated after delivery of TRT, 
and this elevated PD-L1 expression may act as a 
biomarker for predicting enhanced anti-tumor 
response by combination therapy of TRT and 
PD-1/PD-L1 mAbs. Moreover, the combination of 
anti-PD-L1 mAb with TRT can improve the effector 
phase of the immune response by activating 
stimulatory T cells in the tumor microenvironment. 
The cytotoxic CD8+ T cells are important T cells in the 
inhibition of tumor growth [13], while 
tumor-infiltrating regulatory T cells (Tregs) are key 
mediators of immune suppression that negatively 
regulate T-cell function and facilitate immune escape 
[34]. Our data showed that the number of CD8+ T cells 
was significantly increased in mice exposed to 
combination therapy than in those given TRT or 
immunotherapy alone, whereas no increase was 
observed in the inhibitory immune cells Tregs, 
indicating that combined TRT and anti-PD-L1 mAb 
enhances host anti-tumor immunity and improves 
anti-tumor efficacy by stimulating CD8+ T cell 
infiltration, which alters the tumor microenvironment 
and results in a synergistic anti-tumor immunity. 
Furthermore, our data indicated that mice with 
complete tumor regression remained tumor free and 
were able to completely reject tumors following 
contralateral rechallenge. This suggests that TRT 
when combined with blockade of PD1/PD-L1 axis 
may generate protective immunologic memory in 
long-term survivors. Taken together, TRT seems to be 
enough to elicit a similarly heightened response when 
combined with PD-L1 blockade as previously seen 
with external beam therapy, even though the 
absorbed dose delivered/dose rate from 177Lu TRT is 
much lower when compared to external-beam 
radiotherapy. 
Another major challenge is identifying the most 
beneficial time window for combining TRT and 
immunotherapy. In preclinical studies involving 
external-beam radiotherapy, immunotherapy has 
been administered either a few days before, 
concurrent with, or after radiotherapy. For example, 
in the study performed by Dewan et al. [13], delaying 
administration of anti-CTLA-4 mAb until 2 days after 
radiotherapy completion resulted in lower 
therapeutic efficacy than when the mAb was given 2 
days before or on the day of radiotherapy completion, 
implying that immunotherapy should not be 
administered too late after radiotherapy. In another 
study by Dovedi et al. [35], an anti-PD-L1 mAb was 
administered on day 1 of the radiotherapy cycle 
(schedule A), day 5 of the cycle (schedule B), or 7 days 
after completion of radiotherapy (schedule C). The 
results showed that sequential treatment (schedule C) 
was ineffective for improving overall survival, and 
that schedules A and B were much more effective. 
Similar findings were observed in the present study, 
which showed that concurrent TRT and anti-PD-L1 
mAb (administered on days 1, 4, and 7 after TRT) 
conferred significantly enhanced anti-tumor efficacy 
and longer overall survival than sequential therapy. 
Both Flow cytometry and multiplexed 
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immunofluorescence analysis demonstrated that TRT 
can lead to an acute increase in PD-L1 expression on T 
cells at early time points (during days 4–7 after TRT), 
whereas no increase was observed at later time points, 
suggesting that sequential therapy with delayed 
blockade of PD-1/PD-L1 signaling axis on later time 
point of TRT may be less effective due to the 
disappearance of transient TRT-induced PD-L1 
expression, thereby missing the optimal time window 
for anti-PD-L1 therapy. Although the detailed 
mechanism not yet has been clarified, the present 
study suggests that delivering TRT shortly before 
immunotherapy may be preferable, as the ICB mAbs 
may not be beneficial without the transient 
immune-activating effects of TRT.  
Consistent with previous studies that use 
external-beam radiotherapy, the present study 
demonstrated that PD-L1 expression is up-regulated 
after TRT delivery, and that it remains elevated for at 
least 7 days after the initial treatment. Our data 
suggest that TRT can improve anti-tumor response, 
while the PD-1/PD-L1 axis can attenuate it. As such, 
early inhibition of this axis may be critical for 
generating a long-lasting, effective anti-tumor 
response. However, it is not yet clear how radiation is 
involved in the modulation of PD-L1 expression. One 
study by Gong et al. [32] implied that radiotherapy 
leads to up-regulation of PD-L1 expression on tumor 
cells through the activation of the P13K/AKT and 
STAT3 pathways, which suggested that 
radiation-induced up-regulation of PD-L1 expression 
is driven by activation of the oncogenic signaling 
pathway. In another study involving anaplastic 
lymphoma kinase-derived pulmonary 
adenocarcinoma, PD-L1 expression was up-regulated 
by activation of STAT3 and hypoxia-inducible 
factor-1α under both normoxic and hypoxic 
conditions [36]. In addition, activation of the 
MEK/ERK signaling pathway is involved in PD-L1 
modulation in NSCLC cells that harbor either 
EML4-ALK rearrangement or EGFR mutations [37]. 
These findings reveal a direct link between oncogenic 
drivers and PD-L1 expression. However, to illustrate 
the detailed mechanisms of oncogenes that drive the 
expression of PD-L1 after radiation, further 
investigation is needed. It should be noted that our 
study also has some limitations. First of all, the whole 
study was only tested in MC38 tumor model, which is 
generally an anti-PD-1/PD-L1 sensitive and 
immunologically “hot” tumor model. Besides, the 
biological behavior and microenvironment of MC38 
murine colon cancer is very different from human 
colon cancer, which usually does not respond to 
immunotherapy unless mismatch repair deficiency 
(dMMR). In addition, our present study mainly 
focused on the effects of combination therapy of 
177Lu-labeled peptides and PD-L1 blockade, the 
mechanism behind could be further explored.  
In summary, we have demonstrated that TRT 
can up-regulate PD-L1 expression, and that TRT 
combined with anti-PD-L1 mAb can stimulate CD8+ T 
cell infiltration, altering the tumor microenvironment 
and resulting in a synergistic anti-tumor immunity in 
MC38 colon carcinoma model. Moreover, our data 
revealed that the time window for this combination 
therapy may be critical to outcome, with concurrent 
rather than sequential therapy being more effective in 
terms of overall survival and long-term tumor control. 
This therapeutic combination may be a promising 
approach to treating metastatic tumors in which TRT 
can be used. Clinical translation of the result would 
suggest that concurrent rather than sequential 
blockade of the PD-1/PD-L1 axis combined with TRT 
improves overall survival and long-term tumor 
control.  
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